Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA-Selected Kidney Disease Devices Still In Early Development

This article was originally published in The Gray Sheet

Executive Summary

Investigational devices from CreatiVasc Medical, Blood Purification Technologies and the University of California, San Francisco were selected for CDRH’s “innovation pathway 2.0” program.

You may also be interested in...



CDRH Launches ‘Innovation Pathway 2.0’ With End-Stage Renal Devices

Participants expect the program to tangibly reduce time to market and improve companies’ prospects for raising money.

CDRH Launches ‘Innovation Pathway 2.0’ With End-Stage Renal Devices

Participants expect the program to tangibly reduce time to market and improve companies’ prospects for raising money.

CDRH Launches ‘Innovation Pathway 2.0’ With End-Stage Renal Devices

Participants expect the program to tangibly reduce time to market and improve companies’ prospects for raising money.

UsernamePublicRestriction

Register

LL018264

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel